BCL6 corepressor like 1Genealiases: BCoR-L1 · CXorf10 · SHUVER
Q-omics provides the consensus-scored BCORL1 profile across patient tissues and cancer cell-line models. BCORL1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, BCORL1 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, BCORL1 RNA expression shows 19,923 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight BLCA, HNSC, and ACC as cancer lineages where BCORL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BCORL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BCORL1 survival associations across molecular data types. BCORL1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (13) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BCORL1 RNA expression–survival associations across cancer types. High BCORL1 expression shows unfavorable associations in BLCA, LIHC, ACC, LGG and UCEC, but favorable associations in KIRC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify BLCA as the clearest survival context for BCORL1 RNA expression.
This table summarizes BCORL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for BCORL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BCORL1 shows lower tumor expression in KICH and THCA and higher tumor expression in HNSC, LIHC, LUAD and CHOL. The HNSC box plot shows higher BCORL1 RNA expression in tumor versus normal tissue (log2 FC = +1.086, t-test p < 0.001).
This table shows molecular features associated with BCORL1 in patient tissues and cancer cell lines. In patient samples, BCORL1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, BCORL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
